ilmscore | Prediction Details
"M Cure expects this ratio to improve in the medium term as it expects its cash flow to remain strong and will be able to manage cautious capital spending appropriately."
By Groww | July 2, 2024 | Pending
From video
Emcure Pharmaceuticals IPO | Apply or Avoid? 00:02:45 - 00:02:54
Interpreted Prediction
Emkay Pharmaceuticals (M Cure) expects its net debt to EBITDA ratio to improve in the medium term due to strong cash flow and appropriate capital spending management.

Prediction Details

Topic
Emkay Pharmaceuticals Financials

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.